Watch this CME/CE/CNE session anytime On Demand.

Educational Objectives

  • Contrast the distinct mechanisms of action and clinical profiles of newer therapeutic regimens for the management of castration-sensitive prostate cancer (CSPC) in the early stages of disease and in the biochemical-recurrence setting
  • Incorporate risk stratification approaches to inform clinical decision-making for managing patients with CSPC
  • Plan strategies for diagnosing and managing AEs associated with newer therapeutic regimens for treating patients with CSPC
  • Facilitate open communication and shared decision-making as part of patient-centered CSPC management


Neal Shore, MD (Program Chair)
Director, CPI, Carolina Urologic Research Center
Myrtle Beach, South Carolina


Jason M. Hafron, MD
Chief Medical Officer and Partner
Michigan Institute of Urology, P.C
Associate Professor
Urology William Beaumont School of Medicine
Oakland University
Director of Robotic Surgery
Beaumont Hospital Royal Oak
West Bloomfield, Michigan

Educational Audience

This activity is designed to meet the educational needs urologists, medical oncologists, and other HCPs responsible for treatment decisions for patients with prostate cancer, as well as primary care providers and other members of a multi-disciplinary care team involved in the management of Adverse Events (AE's).


This program expires August 30, 2022.

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Purpose: This program would be beneficial for nurses involved in caring for patients with prostate cancer.

Credit: 1.0 ANCC Contact Hour


Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient out­comes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at


Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring event at [email protected]


This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). 

This activity is supported by an educational grant from Astellas.  

 Managing Castration-sensitive Prostate Cancer:
How Does Your Approach Compare with the Experts’?